Jared J Herr, MD
Advanced Heart Failure and Transplant Cardiology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Herr’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A110432 · Current
Licensed to practise in California · since 2009 · expires 2027-09-30 · University of Texas Medical Branch at Galveston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$205,268
Medicare paid this office $205,268 for 519 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 35 | $64,161 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $24,124 | $105 |
| Return visit (30+ min) | 101 | $21,717 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 119 | $17,405 | $134 |
| Long return visit (40+ min) | 84 | $15,897 | $120 |
See all 22 services
| Critical care, first 30-74 minutes | 35 | $64,161 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $24,124 | $105 |
| Return visit (30+ min) | 101 | $21,717 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 119 | $17,405 | $134 |
| Long return visit (40+ min) | 84 | $15,897 | $120 |
| Evaluation of lower heart chamber assist device | 47 | $9,869 | $34 |
| Return visit (30+ min) | 54 | $8,196 | $78 |
| Biopsy of heart muscle | 13 | $7,828 | $191 |
| Long return visit (40+ min) | 29 | $6,341 | $159 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 55 | $5,067 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,695 | $154 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 247 | $3,154 | $12 |
| New patient visit (60+ min) | 16 | $3,132 | $196 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,015 | $215 |
| New patient visit (45+ min) | 12 | $1,786 | $149 |
| Insertion of tube in right heart chambers for measurement | 13 | $1,357 | $97 |
| Short return visit (20+ min) | 12 | $1,229 | $82 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 40 | $686 | $15 |
| Ultrasound of heart, follow-up | 11 | $438 | $22 |
| Ultrasonic guidance for blood vessel access | 17 | $379 | $11 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $294 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 13 | $158 | $12 |
Who their Medicare patients are
519 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 12% · Women 45% · Also on Medicaid 15% · Health risk score 1.62. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 2.53.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Heart failure 44% · Chronic kidney disease 38% · Atrial fibrillation 38% · Diabetes 32% · Depression 17% · Cancer 14% · COPD 14% · Stroke 8% · Dementia 6%.
The office billed $962,906, Medicare allowed $267,648 and paid $205,268; for 2,206 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 519 | 2,206 | 75 | 1.62 | $962,906 | $205,268 |
| 2023 | 478 | 2,132 | 75 | 1.72 | $949,928 | $216,670 |
| 2022 | 478 | 1,884 | 74 | 1.63 | $781,092 | $189,212 |
| 2021 | 429 | 1,807 | 74 | 1.64 | $776,445 | $192,466 |
| 2020 | 386 | 1,373 | 73 | 1.95 | $488,027 | $124,613 |
| 2019 | 233 | 1,570 | 71 | 2.60 | $680,657 | $170,039 |
| 2018 | 200 | 1,120 | 70 | 3.01 | $448,431 | $113,741 |
| 2017 | 197 | 1,449 | 70 | 2.71 | $604,799 | $154,741 |
| 2016 | 612 | 1,520 | 76 | 1.63 | $494,965 | $135,466 |
| 2015 | 136 | 311 | 79 | 1.30 | $106,201 | $33,929 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Critical care, first 30-74 minutes | 57 | $73,457 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $31,793 | $107 |
| Return visit (30+ min) | 88 | $19,350 | $109 |
| Long return visit (40+ min) | 74 | $17,086 | $126 |
| Long return visit (40+ min) | 52 | $14,972 | $158 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 105 | $14,923 | $130 |
| Evaluation of lower heart chamber assist device | 43 | $10,981 | $35 |
| Return visit (30+ min) | 39 | $7,078 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 50 | $3,687 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,567 | $155 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 213 | $2,899 | $13 |
| New patient visit (60+ min) | 15 | $2,899 | $193 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,816 | $235 |
| New patient visit (45+ min) | 11 | $1,668 | $152 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $499 | $29 |
| Ultrasonic guidance for blood vessel access | 12 | $209 | $12 |
| 3d radiographic procedure | 12 | $112 | $9 |
2022: 14 services
| Critical care, first 30-74 minutes | 41 | $44,410 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $32,645 | $94 |
| Long return visit (40+ min) | 84 | $18,095 | $127 |
| Return visit (30+ min) | 78 | $17,829 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 123 | $17,687 | $132 |
| Long return visit (40+ min) | 59 | $17,673 | $168 |
| Evaluation of lower heart chamber assist device | 39 | $7,174 | $35 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,478 | $180 |
| Return visit (30+ min) | 26 | $4,326 | $82 |
| New patient visit (60+ min) | 16 | $3,015 | $188 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 199 | $2,522 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 33 | $2,409 | $62 |
| New patient visit (60+ min) | 12 | $1,990 | $166 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $282 | $22 |
2021: 16 services
| Critical care, first 30-74 minutes | 42 | $62,073 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $27,083 | $93 |
| Return visit (30+ min) | 78 | $18,670 | $112 |
| Long return visit (40+ min) | 38 | $14,847 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $14,225 | $148 |
| Long return visit (40+ min) | 61 | $13,017 | $126 |
| Evaluation of lower heart chamber assist device | 30 | $6,173 | $35 |
| Return visit (30+ min) | 28 | $5,592 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,201 | $179 |
| New patient visit (60+ min) | 20 | $4,020 | $201 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $3,859 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 176 | $2,351 | $13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $458 | $31 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $322 | $23 |
| Ultrasonic guidance for blood vessel access | 12 | $321 | $12 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $222 | $16 |
2020: 15 services
| Critical care, first 30-74 minutes | 25 | $25,961 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $21,425 | $95 |
| Return visit (30+ min) | 70 | $14,566 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 78 | $12,159 | $150 |
| Long return visit (40+ min) | 54 | $10,273 | $98 |
| Evaluation of lower heart chamber assist device | 29 | $6,999 | $43 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,500 | $180 |
| Return visit (30+ min) | 29 | $4,247 | $66 |
| Long return visit (40+ min) | 18 | $3,789 | $126 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 33 | $2,568 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 166 | $2,405 | $14 |
| New patient visit (45+ min) | 13 | $2,036 | $157 |
| External ekg recording for more than 48 hours up to 21 days | 17 | $477 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $470 | $24 |
| Ultrasonic guidance for blood vessel access | 11 | $235 | $13 |
2019: 11 services
| Critical care, first 30-74 minutes | 49 | $59,198 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $22,959 | $94 |
| Return visit (30+ min) | 76 | $19,925 | $94 |
| Long return visit (40+ min) | 63 | $11,980 | $95 |
| Evaluation of lower heart chamber assist device | 28 | $9,265 | $41 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $8,490 | $189 |
| Long return visit (40+ min) | 31 | $7,500 | $127 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $6,321 | $67 |
| Return visit (30+ min) | 27 | $4,694 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,376 | $182 |
| Ultrasonic guidance for blood vessel access | 18 | $518 | $13 |
2018: 13 services
| Critical care, first 30-74 minutes | 26 | $26,168 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $16,768 | $93 |
| Return visit (30+ min) | 64 | $12,937 | $91 |
| Long return visit (40+ min) | 53 | $12,241 | $95 |
| Long return visit (40+ min) | 30 | $7,140 | $135 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 22 | $6,123 | $204 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $5,405 | $64 |
| Biopsy of heart muscle | 11 | $5,341 | $178 |
| Evaluation of lower heart chamber assist device | 21 | $5,071 | $40 |
| Return visit (30+ min) | 25 | $3,222 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,190 | $177 |
| Insertion of tube in right heart chambers for measurement | 18 | $2,129 | $101 |
| Ultrasonic guidance for blood vessel access | 24 | $559 | $12 |
2017: 11 services
| Critical care, first 30-74 minutes | 40 | $61,042 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $20,169 | $93 |
| Return visit (30+ min) | 60 | $12,301 | $92 |
| Long return visit (40+ min) | 45 | $11,858 | $89 |
| Evaluation of lower heart chamber assist device | 20 | $7,965 | $40 |
| Long return visit (40+ min) | 29 | $7,011 | $132 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 60 | $5,523 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,240 | $175 |
| Insertion of tube in right heart chambers for measurement | 23 | $3,713 | $95 |
| Return visit (30+ min) | 21 | $3,617 | $70 |
| Ultrasonic guidance for blood vessel access | 23 | $524 | $13 |
2016: 19 services
| Critical care, first 30-74 minutes | 18 | $24,377 | $197 |
| Return visit (30+ min) | 100 | $20,903 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $17,568 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $9,658 | $225 |
| Long return visit (40+ min) | 50 | $9,146 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,235 | $179 |
| Long return visit (40+ min) | 31 | $5,799 | $98 |
| Short return visit (20+ min) | 54 | $4,497 | $64 |
| New patient visit (45+ min) | 33 | $4,383 | $133 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $4,058 | $271 |
| New patient visit (60+ min) | 21 | $3,858 | $184 |
| Evaluation of lower heart chamber assist device | 12 | $3,267 | $41 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 212 | $2,933 | $14 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,865 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,727 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,188 | $63 |
| External ekg recording for more than 48 hours up to 21 days | 25 | $639 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 25 | $573 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 73 | $503 | $6 |
2015: 8 services
| Return visit (30+ min) | 43 | $7,135 | $106 |
| New patient visit (45+ min) | 30 | $4,803 | $160 |
| New patient visit (60+ min) | 21 | $4,183 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,235 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,200 | $68 |
| Long return visit (40+ min) | 21 | $3,133 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,153 | $98 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 17 | $152 | $7 |
Medicaid work
$643 in 2024
Medicaid paid $643 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $643 |
| 2024 | 12 | 1 | 12 | $643 |
| 2023 | 28 | 2 | 13 | $2,193 |
| 2022 | 98 | 3 | 15 | $8,560 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $1,221 |
| Return visit (30+ min) | 13 | $972 |
2022
| Long return visit (40+ min) | 32 | $4,566 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 52 | $2,668 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $1,326 |
Drugs they prescribed that Part D paid
$2,516,823
Pharmacies billed $2,516,823 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,760) in 2024. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 0%.
2,098 generic and 662 brand-name prescriptions · $2,516,823 in drug cost · 50 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 63 | $1,611,132 | $25,574 |
| Entresto | 191 | $233,481 | $1,222 |
| Jardiance | 130 | $160,537 | $1,235 |
| Camzyos | 17 | $134,953 | $7,938 |
| Eliquis | 88 | $125,268 | $1,424 |
See all 40 drugs
| Vyndamax | 63 | $1,611,132 | $25,574 |
| Entresto | 191 | $233,481 | $1,222 |
| Jardiance | 130 | $160,537 | $1,235 |
| Camzyos | 17 | $134,953 | $7,938 |
| Eliquis | 88 | $125,268 | $1,424 |
| Farxiga | 94 | $85,746 | $912 |
| Xarelto | 15 | $24,439 | $1,629 |
| Dapagliflozin | 12 | $9,580 | $798 |
| Repatha Sureclick | 13 | $8,347 | $642 |
| Metoprolol | 208 | $3,852 | $19 |
| Mycophenolate Mofetil | 32 | $2,736 | $85 |
| Atorvastatin | 280 | $2,658 | $9 |
| Rosuvastatin | 82 | $1,944 | $24 |
| Tacrolimus | 38 | $1,784 | $47 |
| Bumetanide | 32 | $1,691 | $53 |
| Losartan | 128 | $1,572 | $12 |
| Ezetimibe | 36 | $1,456 | $40 |
| Hydralazine | 50 | $1,164 | $23 |
| Doxycycline Hyclate | 11 | $1,065 | $97 |
| Potassium Chloride | 57 | $1,044 | $18 |
| Carvedilol | 117 | $1,032 | $9 |
| Amlodipine Besylate | 108 | $903 | $8 |
| Isosorbide Mononitrate Er | 41 | $882 | $22 |
| Spironolactone | 156 | $842 | $5 |
| Methotrexate | 26 | $829 | $32 |
| Valganciclovir | 17 | $807 | $47 |
| Telmisartan | 16 | $664 | $42 |
| Furosemide | 102 | $637 | $6 |
| Pravastatin | 39 | $499 | $13 |
| Lisinopril | 89 | $492 | $6 |
| Warfarin | 31 | $364 | $12 |
| Pantoprazole | 26 | $306 | $12 |
| Atenolol | 22 | $269 | $12 |
| Clopidogrel | 21 | $239 | $11 |
| Bisoprolol | 12 | $188 | $16 |
| Simvastatin | 18 | $114 | $6 |
| Hydrochlorothiazide | 27 | $108 | $4 |
| Tamsulosin | 11 | $43 | $4 |
| Amoxicillin | 11 | $16 | $1 |
| Trazodone | 19 | $10 | $1 |
Year by year
| 2024 | 2,760 | 284 | 0% (0) | 24% | $2,516,823 |
| 2023 | 2,278 | 247 | 0% (0) | None | $1,259,003 |
| 2022 | 1,706 | 240 | 0% (0) | 19% | $704,831 |
| 2021 | 1,512 | 199 | 0% (0) | 19% | $563,295 |
| 2020 | 1,448 | 175 | None | 18% | $371,720 |
| 2019 | 1,594 | 172 | 0% (0) | 15% | $155,875 |
| 2018 | 1,512 | 163 | None | 16% | $128,173 |
| 2017 | 1,754 | 185 | 0% (0) | None | $182,631 |
| 2016 | 1,045 | 149 | None | None | $104,749 |
| 2015 | 168 | 48 | None | 19% | $8,975 |
| 2014 | 22 | None | 0% (0) | None | $539 |
| 2013 | 18 | None | 0% (0) | 0% | $296 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Vyndamax | 22 | $590,023 | $26,819 |
| Entresto | 151 | $190,998 | $1,265 |
| Eliquis | 81 | $104,876 | $1,295 |
| Camzyos | 13 | $103,574 | $7,967 |
| Jardiance | 97 | $89,720 | $925 |
| Farxiga | 96 | $89,102 | $928 |
| Xarelto | 21 | $26,000 | $1,238 |
| Everolimus | 18 | $8,963 | $498 |
| Tacrolimus | 31 | $5,254 | $169 |
| Metoprolol | 193 | $4,188 | $22 |
| Atorvastatin | 226 | $3,974 | $18 |
| Mycophenolate Mofetil | 17 | $3,292 | $194 |
| Bumetanide | 39 | $2,973 | $76 |
| Isosorbide Mononitrate Er | 39 | $2,217 | $57 |
| Losartan | 121 | $2,189 | $18 |
| Hydralazine | 66 | $2,048 | $31 |
| Carvedilol | 115 | $1,969 | $17 |
| Potassium Chloride | 39 | $1,528 | $39 |
| Valsartan | 14 | $1,488 | $106 |
| Spironolactone | 140 | $1,255 | $9 |
| Labetalol | 12 | $1,142 | $95 |
| Amlodipine Besylate | 77 | $1,031 | $13 |
| Rosuvastatin | 54 | $958 | $18 |
| Warfarin | 37 | $943 | $25 |
| Ezetimibe | 18 | $888 | $49 |
| Azithromycin | 11 | $872 | $79 |
| Pravastatin | 35 | $837 | $24 |
| Methotrexate | 15 | $689 | $46 |
| Lisinopril | 73 | $586 | $8 |
| Furosemide | 83 | $534 | $6 |
| Clopidogrel | 20 | $477 | $24 |
| Pantoprazole | 27 | $448 | $17 |
| Atenolol | 18 | $206 | $11 |
| Trazodone | 12 | $113 | $9 |
| Hydrochlorothiazide | 32 | $100 | $3 |
| Amoxicillin | 12 | $9 | $1 |
2022: 28 drugs
| Vyndamax | 18 | $362,992 | $20,166 |
| Entresto | 86 | $87,207 | $1,014 |
| Eliquis | 55 | $58,926 | $1,071 |
| Farxiga | 57 | $42,439 | $745 |
| Jardiance | 47 | $39,588 | $842 |
| Everolimus | 18 | $19,626 | $1,090 |
| Bumetanide | 49 | $4,318 | $88 |
| Tacrolimus | 21 | $3,906 | $186 |
| Metoprolol | 132 | $2,919 | $22 |
| Hydralazine | 90 | $2,535 | $28 |
| Atorvastatin | 152 | $1,772 | $12 |
| Isosorbide Mononitrate Er | 36 | $1,535 | $43 |
| Losartan | 106 | $1,492 | $14 |
| Carvedilol | 104 | $1,201 | $12 |
| Potassium Chloride | 27 | $1,102 | $41 |
| Pravastatin | 49 | $1,050 | $21 |
| Doxycycline Hyclate | 14 | $950 | $68 |
| Valsartan | 24 | $943 | $39 |
| Amlodipine Besylate | 70 | $872 | $12 |
| Warfarin | 37 | $690 | $19 |
| Pantoprazole | 35 | $633 | $18 |
| Spironolactone | 85 | $588 | $7 |
| Furosemide | 64 | $554 | $9 |
| Lisinopril | 62 | $522 | $8 |
| Rosuvastatin | 24 | $436 | $18 |
| Torsemide | 13 | $383 | $29 |
| Methotrexate | 12 | $175 | $15 |
| Hydrochlorothiazide | 23 | $140 | $6 |
2021: 27 drugs
| Sivextro | 13 | $162,540 | $12,503 |
| Eliquis | 70 | $66,329 | $948 |
| Entresto | 68 | $64,260 | $945 |
| Farxiga | 17 | $9,485 | $558 |
| Bumetanide | 56 | $6,262 | $112 |
| Isosorbide Dinitrate | 25 | $3,752 | $150 |
| Hydralazine | 88 | $2,914 | $33 |
| Metoprolol | 113 | $2,512 | $22 |
| Atorvastatin | 115 | $2,010 | $17 |
| Carvedilol | 123 | $1,815 | $15 |
| Mycophenolate Mofetil | 13 | $1,724 | $133 |
| Isosorbide Mononitrate Er | 32 | $1,680 | $53 |
| Losartan | 88 | $1,346 | $15 |
| Rosuvastatin | 50 | $1,202 | $24 |
| Potassium Chloride | 24 | $987 | $41 |
| Amlodipine Besylate | 56 | $873 | $16 |
| Furosemide | 59 | $849 | $14 |
| Methotrexate | 21 | $701 | $33 |
| Pantoprazole | 36 | $677 | $19 |
| Pravastatin | 31 | $667 | $22 |
| Spironolactone | 56 | $524 | $9 |
| Lisinopril | 45 | $485 | $11 |
| Warfarin | 35 | $477 | $14 |
| Valsartan | 12 | $266 | $22 |
| Omeprazole | 15 | $241 | $16 |
| Hydrochlorothiazide | 41 | $190 | $5 |
| Amoxicillin | 11 | $64 | $6 |
2020: 27 drugs
| Eliquis | 58 | $63,463 | $1,094 |
| Entresto | 52 | $40,393 | $777 |
| Zortress | 12 | $25,818 | $2,151 |
| Valganciclovir | 12 | $5,995 | $500 |
| Bumetanide | 58 | $5,757 | $99 |
| Atorvastatin | 129 | $2,871 | $22 |
| Isosorbide Dinitrate | 15 | $2,628 | $175 |
| Rosuvastatin | 28 | $2,251 | $80 |
| Hydralazine | 77 | $2,245 | $29 |
| Tacrolimus | 33 | $2,210 | $67 |
| Mycophenolate Mofetil | 21 | $1,999 | $95 |
| Metoprolol | 80 | $1,714 | $21 |
| Carvedilol | 104 | $1,457 | $14 |
| Potassium Chloride | 37 | $1,178 | $32 |
| Isosorbide Mononitrate Er | 31 | $1,047 | $34 |
| Losartan | 68 | $1,016 | $15 |
| Warfarin | 50 | $861 | $17 |
| Furosemide | 72 | $699 | $10 |
| Pantoprazole | 36 | $689 | $19 |
| Pravastatin | 36 | $673 | $19 |
| Lisinopril | 50 | $593 | $12 |
| Amlodipine Besylate | 40 | $446 | $11 |
| Spironolactone | 48 | $424 | $9 |
| Allopurinol | 18 | $348 | $19 |
| Sulfamethoxazole-Trimethoprim | 18 | $163 | $9 |
| Hydrochlorothiazide | 26 | $86 | $3 |
| Metoprolol | 13 | $46 | $4 |
2019: 32 drugs
| Eliquis | 78 | $67,126 | $861 |
| Entresto | 34 | $21,913 | $645 |
| Valganciclovir | 19 | $7,711 | $406 |
| Bumetanide | 53 | $4,228 | $80 |
| Mycophenolate Mofetil | 26 | $2,923 | $112 |
| Metoprolol | 66 | $2,784 | $42 |
| Amiodarone | 16 | $2,324 | $145 |
| Atorvastatin | 102 | $2,012 | $20 |
| Isosorbide Dinitrate | 27 | $1,898 | $70 |
| Hydralazine | 70 | $1,571 | $22 |
| Rosuvastatin | 31 | $1,433 | $46 |
| Warfarin | 57 | $1,396 | $24 |
| Isosorbide Mononitrate Er | 50 | $1,389 | $28 |
| Lisinopril | 106 | $1,302 | $12 |
| Potassium Chloride | 38 | $1,277 | $34 |
| Tacrolimus | 24 | $1,224 | $51 |
| Pravastatin | 83 | $1,115 | $13 |
| Carvedilol | 83 | $1,015 | $12 |
| Losartan | 82 | $987 | $12 |
| Omega-3 Acid Ethyl Esters | 12 | $863 | $72 |
| Furosemide | 83 | $827 | $10 |
| Nystatin | 18 | $764 | $42 |
| Amlodipine Besylate | 56 | $484 | $9 |
| Mirtazapine | 14 | $345 | $25 |
| Spironolactone | 43 | $344 | $8 |
| Pantoprazole | 25 | $342 | $14 |
| Sulfamethoxazole-Trimethoprim | 29 | $164 | $6 |
| Amoxicillin | 16 | $159 | $10 |
| Hydrochlorothiazide | 35 | $150 | $4 |
| Clopidogrel | 11 | $131 | $12 |
| Metoprolol | 14 | $44 | $3 |
| Atenolol | 13 | $22 | $2 |
2018: 35 drugs
| Eliquis | 72 | $49,299 | $685 |
| Entresto | 44 | $20,576 | $468 |
| Bumetanide | 48 | $3,766 | $78 |
| Metoprolol | 82 | $3,539 | $43 |
| Valganciclovir | 12 | $3,281 | $273 |
| Hydralazine | 94 | $2,858 | $30 |
| Isosorbide Mononitrate Er | 45 | $1,917 | $43 |
| Isosorbide Dinitrate | 22 | $1,792 | $81 |
| Atorvastatin | 84 | $1,774 | $21 |
| Potassium Chloride | 34 | $1,673 | $49 |
| Carvedilol | 105 | $1,672 | $16 |
| Rosuvastatin | 30 | $1,264 | $42 |
| Losartan | 95 | $1,221 | $13 |
| Warfarin | 37 | $1,151 | $31 |
| Mycophenolate Mofetil | 15 | $1,137 | $76 |
| Lisinopril | 93 | $882 | $9 |
| Doxycycline Hyclate | 15 | $849 | $57 |
| Furosemide | 90 | $775 | $9 |
| Tacrolimus | 11 | $592 | $54 |
| Nystatin | 12 | $509 | $42 |
| Pravastatin | 41 | $483 | $12 |
| Spironolactone | 36 | $391 | $11 |
| Pantoprazole | 29 | $387 | $13 |
| Diltiazem 24hr Er | 13 | $379 | $29 |
| Tamsulosin | 16 | $366 | $23 |
| Amlodipine Besylate | 48 | $211 | $4 |
| Sulfamethoxazole-Trimethoprim | 14 | $188 | $13 |
| Prednisone | 15 | $183 | $12 |
| Amoxicillin | 19 | $169 | $9 |
| Levothyroxine | 13 | $155 | $12 |
| Digox | 12 | $134 | $11 |
| Trazodone | 13 | $105 | $8 |
| Atenolol | 14 | $79 | $6 |
| Hydrochlorothiazide | 22 | $62 | $3 |
| Metoprolol | 15 | $41 | $3 |
2017: 42 drugs
| Eliquis | 117 | $57,592 | $492 |
| Valganciclovir | 14 | $21,985 | $1,570 |
| Myfortic | 11 | $20,083 | $1,826 |
| Entresto | 19 | $8,506 | $448 |
| Bumetanide | 49 | $5,846 | $119 |
| Xarelto | 13 | $5,815 | $447 |
| Brilinta | 11 | $3,664 | $333 |
| Metoprolol | 102 | $3,594 | $35 |
| Hydralazine | 95 | $2,152 | $23 |
| Eplerenone | 16 | $2,060 | $129 |
| Mycophenolate Mofetil | 22 | $1,977 | $90 |
| Isosorbide Dinitrate | 28 | $1,930 | $69 |
| Tacrolimus | 25 | $1,917 | $77 |
| Amiodarone | 19 | $1,496 | $79 |
| Atorvastatin | 79 | $1,475 | $19 |
| Carvedilol | 113 | $1,242 | $11 |
| Warfarin | 69 | $1,164 | $17 |
| Dilt-Xr | 14 | $1,025 | $73 |
| Digoxin | 24 | $924 | $39 |
| Prednisone | 35 | $907 | $26 |
| Isosorbide Mononitrate Er | 39 | $885 | $23 |
| Losartan | 76 | $701 | $9 |
| Pravastatin | 30 | $701 | $23 |
| Diltiazem 24hr Er | 20 | $631 | $32 |
| Labetalol | 15 | $583 | $39 |
| Furosemide | 96 | $473 | $5 |
| Lisinopril | 92 | $473 | $5 |
| Klor-Con 10 | 12 | $457 | $38 |
| Potassium Chloride | 29 | $435 | $15 |
| Digox | 13 | $432 | $33 |
| Spironolactone | 65 | $429 | $7 |
| Amlodipine Besylate | 73 | $397 | $5 |
| Tamsulosin | 21 | $390 | $19 |
| Omeprazole | 19 | $302 | $16 |
| Lovastatin | 15 | $279 | $19 |
| Levothyroxine | 13 | $206 | $16 |
| Torsemide | 12 | $182 | $15 |
| Metoprolol | 24 | $142 | $6 |
| Pantoprazole | 17 | $113 | $7 |
| Atenolol | 16 | $100 | $6 |
| Famotidine | 14 | $64 | $5 |
| Hydrochlorothiazide | 22 | $54 | $2 |
2016: 22 drugs
| Eliquis | 116 | $45,406 | $391 |
| Pradaxa | 12 | $4,878 | $407 |
| Bumetanide | 32 | $4,070 | $127 |
| Metoprolol | 97 | $2,886 | $30 |
| Atorvastatin | 65 | $1,341 | $21 |
| Hydralazine | 41 | $1,010 | $25 |
| Potassium Chloride | 32 | $822 | $26 |
| Digox | 18 | $716 | $40 |
| Diltiazem 24hr Er | 21 | $666 | $32 |
| Digoxin | 19 | $566 | $30 |
| Carvedilol | 55 | $525 | $10 |
| Metoprolol | 32 | $502 | $16 |
| Losartan | 43 | $451 | $10 |
| Nitrostat | 12 | $436 | $36 |
| Furosemide | 77 | $413 | $5 |
| Lisinopril | 64 | $367 | $6 |
| Spironolactone | 34 | $345 | $10 |
| Isosorbide Mononitrate Er | 11 | $300 | $27 |
| Metolazone | 11 | $281 | $26 |
| Warfarin | 15 | $260 | $17 |
| Clopidogrel | 11 | $237 | $22 |
| Amlodipine Besylate | 37 | $225 | $6 |
2015: 4 drugs
| Metoprolol | 16 | $518 | $32 |
| Carvedilol | 12 | $109 | $9 |
| Metoprolol | 12 | $69 | $6 |
| Furosemide | 21 | $62 | $3 |
Money from drug and device companies
$1,296 in 2025
| 2025 | 8 | 13 | None | $1,296 |
| 2024 | 8 | 19 | None | $2,679 |
| 2023 | 2 | 2 | None | $260 |
| 2022 | 3 | 11 | None | $1,889 |
| 2021 | 4 | 13 | None | $324 |
| 2020 | 5 | 11 | None | $1,165 |
| 2019 | 7 | 29 | $1,050 | $4,017 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CVRx | Barostim Neo System | $1,001 | 6 payments
|
| Abiomed | None | $123 | 1 payment
|
| Paragonix Technologies | Sherpapak | $44 | 1 payment
|
| Pfizer | Vyndaqel | $31 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $28 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $27 | 1 payment
|
See all 13 published payments
| Abiomed | Meals · 2025-12-19 | None | $123 |
| CVRx | Travel · 2025-12-08 | Barostim Neo System | $34 |
| CVRx | Travel · 2025-12-08 | Barostim Neo System | $547 |
| Pfizer | Meals · 2025-12-08 | Vyndaqel | $31 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Leqvio | $27 |
| Paragonix Technologies | Meals · 2025-10-01 | Sherpapak | $44 |
| Abbvie | Meals · 2025-07-08 | Synthroid | $16 |
| Alnylam Pharmaceuticals | Meals · 2025-05-29 | Onpattro | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-11 | None | $26 |
| CVRx | Meals · 2025-01-14 | Barostim Neo System | $108 |
| CVRx | Meals · 2025-01-11 | Barostim Neo System | $214 |
| CVRx | Meals · 2025-01-11 | Barostim Neo System | $63 |
| CVRx | Meals · 2025-01-10 | Barostim Neo System | $35 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,679
| CVRx | Barostim Neo System | $2,094 | 9 payments
|
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $183 | 3 payments
|
| Abiomed | Impella | $137 | 2 payments
|
| Impulse Dynamics (USA) | Optimizer | $129 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $44 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $42 | 1 payment
|
| One Lambda | None | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $21 | 1 payment
|
2023: $260
| CVRx | Barostim Neo System | $138 | 1 payment
|
| Sanofi-Aventis U.S. | None | $122 | 1 payment
|
2022: $1,889
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $1,777 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | None | $99 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $13 | 1 payment
|
2021: $324
| Abbott Laboratories | Heartmate 3 Left Ventricular Assist Device | $219 | 7 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $65 | 4 payments
|
| HeartFlow | Ffrct | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
2020: $1,165
| Abbott Laboratories | Cardiomems Hf System | $1,014 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $97 | 2 payments
|
| Amgen | Corlanor | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16 | 1 payment
|
| iRhythm Technologies | Zio Patch | $16 | 1 payment
|
2019: $4,017
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $3,532 | 14 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $232 | 6 payments
|
| CathWorks | Ffrangio System | $152 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $36 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $27 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $22 | 1 payment
|
| iRhythm Technologies | Zio Patch | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Abbott Laboratories · Investigation To Optimize Hemodynamic Management of Heartmate II Left Ventricular Assist Device Patients Using the Cardiomems Pulmonary Artery Pressure Sensor in Advanced Heart Failure (Intellect 2-Hf) · 2019 | Their institution | $17,597 |
| Abbott Laboratories · Hemodynamic Guided Monitoring in Heart Failure (Hf) Trial (Guide-Hf) · 2019 | Their institution | $15,753 |
| Abbott Laboratories · Hemodynamic-Guided Management of Heart Failure · 2020 | Their institution | $15,441 |
| Abbott Laboratories · Hemodynamic Guided Monitoring in Heart Failure (Hf) Trial · 2021 | Their institution | $8,271 |
| Abbott Laboratories · Investigation To Optimize Hemodynamic Management of Heartmate II Left Ventricular Assist Device Patients Using the Cardiomems Pulmonary Artery Pressure Sensor in Advanced Heart Failure (Intellect 2-Hf) · 2020 | Their institution | $7,241 |
| Abbott Laboratories · Hemodynamic-Guided Management of Heart Failure · 2022 | Their institution | $2,926 |
| Abbott Laboratories · Hemodynamic-Guided Management of Heart Failure · 2023 | Their institution | $2,000 |
| Abbott Laboratories · Cardiomems Hf System Post Approval Study · 2019 | Their institution | $790 |
| Abbott Laboratories · Triluminate Pivotal Trial · 2019 | Their institution | $45 |
Professional record
- NPI
- 1184959272
- Licence
- CA A110432California A110432: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2009-10-07
- NPI last updated
- 2020-05-29
- NPI record certified
- 2020-05-29
This is when the NPI record was last certified, not a medical board exam.